Recurrence after successful parathyroidectomy-Who should we worry about?

Surgery. 2022 Jan;171(1):40-46. doi: 10.1016/j.surg.2021.06.035. Epub 2021 Jul 31.

Abstract

Background: Preventing cervical reoperations is important-especially after parathyroidectomy. We sought to examine early predictors of recurrence of primary hyperparathyroidism after surgical cure.

Methods: Adult patients with sporadic primary hyperparathyroidism treated with parathyroidectomy between September 1, 1997, and September 1, 2019, with confirmed eucalcemia at 6 months postoperatively were identified. Recurrence was defined as hypercalcemia (>10.2 mg/dL) with an elevated or nonsuppressed parathyroid hormone level on subsequent follow-up.

Results: Parathyroidectomy was performed in 522 patients (median age, 62.1 years, 77% female) with the majority undergoing planned minimally invasive parathyroidectomy (85.4%, n = 446). After a median follow-up of 30.9 months, 13 patients (2.5%) recurred (median time to recurrence 50.2 months, interquartile range 27.9-66.5), all of whom underwent planned minimally invasive parathyroidectomy (n = 13/446, 2.9%). Recurrence was more common in those with higher (but still normal) 6-month calcium (10.1 vs 9.3 mg/dL, P < .001) or parathyroid hormone values (64 vs 46 pg/mL, P < .01). Multivariate analysis revealed that age >66.5 years, calcium ≥9.8mg/dL and parathyroid hormone ≥80 pg/mL at 6 months were associated with increased risk of recurrence. In addition, the presence of at least 1 preoperative imaging study that conflicted with intraoperative findings among minimally invasive parathyroidectomy patients (n = 446) was associated with increased risk of recurrence (hazard ratio 4.93, 95% confidence interval 1.25-16.53, P = .016).

Conclusion: Recurrence of sporadic primary hyperparathyroidism after initial surgical cure in the era of minimally invasive parathyroidectomy is 2.5%. Identification of those at risk for recurrence using 6-month serum calcium ≥9.8 mg/dL, parathyroid hormone ≥80 pg/mL, and/or potentially conflicting localization studies may inform surveillance strategies.

MeSH terms

  • Aged
  • Calcium / blood
  • Female
  • Follow-Up Studies
  • Humans
  • Hypercalcemia / blood
  • Hypercalcemia / diagnosis
  • Hypercalcemia / epidemiology
  • Hypercalcemia / surgery*
  • Hyperparathyroidism, Primary / blood
  • Hyperparathyroidism, Primary / diagnosis
  • Hyperparathyroidism, Primary / epidemiology
  • Hyperparathyroidism, Primary / surgery*
  • Male
  • Middle Aged
  • Minimally Invasive Surgical Procedures / statistics & numerical data*
  • Parathyroid Hormone / blood
  • Parathyroidectomy / methods
  • Parathyroidectomy / statistics & numerical data*
  • Recurrence
  • Retrospective Studies
  • Risk Assessment / methods
  • Risk Assessment / statistics & numerical data
  • Treatment Outcome

Substances

  • Parathyroid Hormone
  • Calcium